Eflornithine clinical trials
Also written DFMO, Vaniqa and IWILFIN.
How each study uses Eflornithine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Eflornithine studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 28 Nov 1990 · ORNIDYL · NDA 019879 (FDA, Drugs@FDA)
- European Union
- 19 Mar 2001 · Vaniqa · EMEA/H/C/000325 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
41 studies that test it; most in 2023 (6)
| Year | Studies |
|---|---|
| 1995 | 1 |
| 1998 | 3 |
| 1999 | 1 |
| 2001 | 3 |
| 2003 | 1 |
| 2004 | 1 |
| 2007 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 2 |
| 2014 | 3 |
| 2015 | 2 |
| 2016 | 3 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 2 |
| 2023 | 6 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 36
Giselle Sholler (7) · National Cancer Institute (NCI) (4) · Cancer Prevention Pharmaceuticals, Inc. (3) · National Skin Centre (2) · University of Alabama at Birmingham (2) · University of Wisconsin, Madison (2) · University of Arizona (2) · Mayo Clinic (2)
Often tested with
Tested in the same studies.
Sulindac (5) · Diclofenac (2) · Diclofenac Sodium Gel (2) · AMXT-1501 dicaprate (2) · Tretinoin (1) · Hydroquinone (1) · Celecoxib (1) · Cyclophosphamide (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3, 1 in phase 3
Studies that test Eflornithine, phase 3 first.
- Sep 2027S0820, Adenoma and Second Primary Prevention TrialPhase 3 · SWOG Cancer Research Network
- Jan 2027Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate CancerPhase 2 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Jun 2027TArgeting Type 1 Diabetes Using POLyamines (TADPOL)Phase 2 · Emily K. Sims
Studies
Open first, then newest update. How each study uses Eflornithine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 43
- Naxitamab Enabled Transplant-Free Study in High-Risk NeuroblastomaRecruitingPhase 2Giselle ShollerNCT07932808Written as DFMO
- Intratumoral Extracellular Metabolic Impact of DFMO and AMXT 1501 in Patients With Diffuse or High Grade GliomaRecruitingEarly Phase 1Mayo ClinicNCT05717153Written as Eflornithine
- Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid TumorsRecruitingPhase 1/2Aminex Therapeutics, Inc.NCT07287917Written as DFMO
- Eflornithine (DFMO) for Ewing Sarcoma and OsteosarcomaRecruitingPhase 2Milton S. Hershey Medical CenterNCT07321912Written as Eflornithine
- DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed MedulloblastomaRecruitingPhase 2Giselle ShollerNCT04696029Written as Difluoromethylornithine
- Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade GliomasRecruitingPhase 1/2Mayo ClinicNCT07468136Written as Eflornithine
- DFMO Maintenance for Patients With Relapsed/Refractory Ewing Sarcoma or OsteosarcomaRecruitingPhase 1/2Montefiore Medical CenterNCT06892678Written as DFMO
- Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate CancerRecruitingPhase 2Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT06059118Written as DFMO
- Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or AstrocytomaRecruitingPhase 1Orbus Therapeutics, Inc.NCT05879367Written as Eflornithine (Dose Level 1)
- Eflornithine (DFMO) and Etoposide for Relapsed/Refractory NeuroblastomaActive, not recruitingPhase 2Giselle ShollerNCT04301843Written as Eflornithine
- To Evaluate the Effectiveness of Topical Eflornithine 9.58% + Hydroquinone 4% + Fluocinolone 0.01% as Compared to Topical Tretinoin 0.05% + Hydroquinone 4% + Fluocinolone 0.01% for the Treatment of MelasmaCompletedPhase 2National Skin CentreNCT07876323Written as Eflornithine 9.58% + Hydroquinone 4% + Fluocinolone 0.01% cream
- S0820, Adenoma and Second Primary Prevention TrialActive, not recruitingPhase 3SWOG Cancer Research NetworkNCT01349881Written as Eflornithine plus sulindac
- Neuroblastoma Maintenance Therapy TrialActive, not recruitingPhase 2Giselle ShollerNCT02679144Written as Difluoromethylornithine (DFMO)
- Chemoprevention of Gastric CarcinogenesisCompletedPhase 2Vanderbilt-Ingram Cancer CenterNCT02794428Written as Eflornithine
- TArgeting Type 1 Diabetes Using POLyamines (TADPOL)Active, not recruitingPhase 2Emily K. SimsNCT05594563Written as DFMO
- Targeting ODC as an Immunotherapeutic Target in STK11 (LKB1) Pathway-Deficient NSCLC (DFMO)SuspendedPhase 1/2H. Lee Moffitt Cancer Center and Research InstituteNCT06219174Written as Difluoromethylornithine
- Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory NeuroblastomaActive, not recruitingPhase 2Children's Oncology GroupNCT03794349Written as Eflornithine Hydrochloride
- Topical Diclofenac and Topical DFMO Chemoprevention Trial in Subjects With a History of Skin CancerCompletedPhase 2University of Alabama at BirminghamNCT04091022Written as Solaraze and Vaniqa
- Efficacy of Eflornithine Hydrochloride Cream in the Treatment of Melasma: A Randomized, Double-blinded, Split-face Controlled StudyCompletedPhase 2National Skin CentreNCT06957834Written as Eflornithine hydrochloride cream
- N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/TopotecanCompletedPhase 1New Approaches to Neuroblastoma Therapy ConsortiumNCT02030964Written as DFMO
See all 43 studies that test Eflornithine →
Given beside what is tested · 4 — Eflornithine is usual care or a partner of the new treatment
- Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and SarcomasRecruitingPhase 1/2Milton S. Hershey Medical CenterNCT06465199Written as Eflornithine (DFMO)
- Oral AMXT 1501 Dicaprate in Combination With IV DFMOTerminatedPhase 1/2Aminex Therapeutics, Inc.NCT05500508Written as DFMO
- Oral AMXT 1501 Dicaprate in Combination With DFMOCompletedPhase 1Aminex Therapeutics, Inc.NCT03536728Written as DFMO
- Eflornithine + Nifurtimox Late-Stage Human African Trypanosomiasis (HAT)in West Nile, UgandaTerminatedPhase 2/3EpicentreNCT00489658Written as Eflornithine plus Nifurtimox combination therapy
As the comparator · 2 — what is tested is compared with Eflornithine
What changed recently
From the registry's own updates since Oct 18, 2026.
Newly registered1
- Naxitamab Enabled Transplant-Free Study in High-Risk NeuroblastomaNov 12, 2026NCT07932808
Codes
What other systems call Eflornithine · ClinicalTrials.gg INT006930
- MeSH (NLM) D000518EflornithineConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) ZQN1G5V6SREFLORNITHINEConfirmed FDA, NLM, Wikidata
- RxNorm 569Confirmed FDA, Wikidata
- Wikidata Q424751(RS)-eflornithineConfirmed FDA, NLM, Wikidata
- Wikidata Q72470623EflornithineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C226EflornithineOne source FDA
- DrugBank DB06243One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000518 | Eflornithine | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | ZQN1G5V6SR | EFLORNITHINE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 569 | — | Confirmed FDA, Wikidata |
| Wikidata | Q424751 | (RS)-eflornithine | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q72470623 | Eflornithine | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C226 | Eflornithine | One source FDA |
| DrugBank | DB06243 | — | One source Wikidata |
Also registered as eflornithine hydrochloride (UNII 4NH22NDW9H · RxNorm 81945).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.